Category: 34784-05-9

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.34784-05-9,6-Bromoisoquinoline,as a common compound, the synthetic route is as follows.

The A6-1 (210mg, 1.01mmol) was dissolved in tetrahydrofuran (10mL), was added bis (pinacolato) borate (305mg, 1.20mmol), KOAc(294mg, 3.00mmol), Pd (dppf) 2Cl2 (80mg, 0.10mmol), purged with nitrogen, refluxed overnight, cooled to room temperature, suction filtered through Celite,The filtrate was spin-dried, the residue was purified by column chromatography (petroleum ether: ethyl acetate = 4: 1) to give a yellow gummy solid (270mg, 106%).

As the paragraph descriping shows that 34784-05-9 is playing an increasingly important role.

Reference£º
Patent; Suzhou Yunxuan Pharmaceutical Co., Ltd.; Zhang, Xiaohu; (54 pag.)CN105254613; (2016); A;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem

34784-05-9, 6-Bromoisoquinoline is a isoquinoline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

D. 1-[(3,3-Dimethyl-3-silabutoxy)methyl]-5-(6-isoquinolyl)-2-(phenylsulfonyl)imidazole. To a solution of 6-bromoisoquinoline (73 mg, 0.35 mmol) in anhydrous DMF (0.75 mL) was added copper(II) oxide (28 mg, 0.35 mmol). The mixture was purged with nitrogen, tetrakis(triphenylphosphine)palladium(0) (55 mg, 0.048 mmol) was added, and then the materials were stirred at 100 C. for 5 minutes in a sealed vial. The vial was cooled to room temperature and then a solution of 5-(1,1-dibutyl-1-stannapentyl)-1-[(3,3-dimethyl-3-silabutoxy)methyl]-2-(phenylsulfonyl)imidazole (200 mg, 0.3.19 mmol) in anhydrous DMF (0.25 mL) was added. The mixture was purged with nitrogen then the sealed reaction was stirred at 105 C. for 8 hours. The reaction was cooled to room temperature, filtered through celite, and the celite rinsed with ethyl acetate. The filtrate was diluted with water, extracted three times with dichloromethane, and the organic layers combined. The organic solution was washed with brine, dried over anhydrous magnesium sulfate, filtered, and volatiles evaporated. The material was purified by chromatography on a normal phase silica gel column with 30 to 100% ethyl acetate in hexanes. Fractions containing clean product were combined and the solvent evaporated. The material was dried under vacuum at 60 C. to provide the title compound (1.2 g, 87%). MS (ESI) m/z 466.2 [M+1]+.

As the paragraph descriping shows that 34784-05-9 is playing an increasingly important role.

Reference£º
Patent; D’Sidocky, Neil R.; Harris, Roy L.; Hegde, Sayee G.; Hilgraf, Robert; McCarrick, Margaret A.; McKie, Jeffrey A.; Mortensen, Deborah S.; Nadolny, Lisa; Perin-Ninkovic, Sophie M.; Sapienza, John J.; Wright, Jonathan L.; US2008/242694; (2008); A1;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.34784-05-9,6-Bromoisoquinoline,as a common compound, the synthetic route is as follows.

[00309] 6-(4-Nitro-lH-pyrazol-l-yl)isoquinoline: A mixture of 4-nitro-lH- pyrazole (510 mg, 4.51 mmol), 6-bromoisoquinoline (375 mg, 1.80 mmol)(commercially available from Gateway Chemical Technology, Inc.), tris(dibenzylideneacetone)dipalladium (0) (165 mg, 180 mumol), 2-ditert-butylphosphino- 2′,4′,6′-triisopropyl-l,r-biphenyl (153 mg, 360 mumol), and cesium carbonate (1.76 g, 5.41 mmol) in dioxane (4 mL) was heated in a sealed vial at 105C for 6 hours. The mixture was cooled to ambient temperature and partitioned between DCM (30 mL) and H2O (30 mL). The layers were separated, and the aqueous layer was extracted with DCM (2 x 20 mL) and 10% MeOH/DCM (30 mL). The combined organic layers were dried (MgSO4) and concentrated under reduced pressure. The resulting yellow solid was dissolved in DCM, evaporated onto silica gel, and purified by flash chromatography (Biotage Si 40+M, 20% to 50% acetone/hexanes) to provide 6-(4-nitro-lH-pyrazol-l-yl)isoquinoline (374 mg, 86% yield) as a white solid. LCMS (API-ES) m/z (%): 241.1 (100%, M++H); 1H NMR (300 MHz, CDCl3) delta ppm 7.76 (d, J=5.8 Hz, IH), 8.01 (dd, J=8.8, 2.2 Hz, IH), 8.14-8.23 (m, 2H), 8.36 (s, IH), 8.65 (d, J=5.8 Hz, IH), 8.83 (s, IH), 9.34 (s, IH).

34784-05-9 6-Bromoisoquinoline 313681, aisoquinoline compound, is more and more widely used in various.

Reference£º
Patent; AMGEN INC.; WO2009/11880; (2009); A2;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem

34784-05-9, 6-Bromoisoquinoline is a isoquinoline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a degassed solution of 2-(4-fluorophenyl)-N-methyl-6-(N- methylmethylsulfonamido)-5-(3-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)phenyl)benzofuran-3-carboxamide (90 mg, 0.189 mmol) and 6-bromo-isoquinoline (51 mg, 0.246 mmol) in dry DMF (1.5 mL) was added Pd(dppf)Cl2 (20 mg) and K3P04 (81 mg, 0.381 mmol) under N2. The mixture was heated to 100 C for about 15 hours. The reaction mixture was cooled to room temperature and filtered. The filtrate was washed with H20, brine, dried over Na2S04, filtered and concentrated in vacuo. The residue obtained was purified using prep- TLC (PE : EtOAc = 2 : 1) to provide 2-(4-fluorophenyl)-5-(3-(isoquinolin-6-yl)phenyl)-N- methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide (Compound 210, 85 mg, 93%). 1H- MR (CDC13, 400 MHz) delta 9.62 (s, 1H), 8.46 (d, J= 6.0 Hz, 1H), 8.38 (s, 1H), 8.31-8.33 (m, 1H), 8.21-8.23 (m, 1H), 8.15 (d, J= 6.0 Hz, 1H), 7.98 (s, 1H), 7.81-7.85 (m, 3H), 7.71-7.72 (m, 1H), 7.51-7.60 (m, 3H), 7.12-7.19 (m, 2H), 6.02-6.03 (m, 1H), 3.02 (s, 3H), 2.89-2.92 (m, 6H). MS (M+H)+: 580.

34784-05-9 6-Bromoisoquinoline 313681, aisoquinoline compound, is more and more widely used in various.

Reference£º
Patent; MERCK SHARP & DOHME CORP.; MCCOMAS, Casey Cameron; LIVERTON, Nigel J.; SOLL, Richard; LI, Peng; PENG, Xuanjia; WU, Hao; WO2011/106986; (2011); A1;,
Isoquinoline – Wikipedia
Isoquinoline | C9H7N – PubChem